Literature DB >> 17371694

[Phonation fistulas today].

Nicolás González Poggioli1, Jesús Herranz González-Botas, Juan Carlos Vázquez Barro, Vania Novoa Juiz, José Martínez Vidal.   

Abstract

OBJECTIVE: To describe our experience with the use of trachea-oesophageal puncture (TEP) after total laryngectomy. MATERIAL AND
METHOD: We have studied retrospectively 96 patients who received a voice prosthesis through tracheoesophageal puncture between October 2000 and December 2005.
RESULTS: The punctures effected were 86 primary (89.6 %) and 10 secondary (10.4 %); of the prostheses, 81 (84.4 %) were Provox(R) type and 74 % of patients used it as their normal means of communication. Reasons for withdrawal included insufficiency and aspiration in 66.7 % (14/21), lack of use in 23.8 % (2/21), granulation tissue, and inflammation in 4.7 % (1/21).
CONCLUSIONS: Voice rehabilitation by TEP and prosthesis was successful in 74 % of our patients with acceptable complications and better results than those obtained by tracheaoesophageal speech. We recommend the use of TEP in those patients who have the motivation and a good oncological and physical assessment.

Entities:  

Mesh:

Year:  2007        PMID: 17371694

Source DB:  PubMed          Journal:  Acta Otorrinolaringol Esp        ISSN: 0001-6519


  3 in total

1.  Analysis of Factors Affecting the Longevity of Voice Prosthesis Following Total Laryngectomy with a Review of Literature.

Authors:  Miguel Mayo-Yáñez
Journal:  Indian J Surg Oncol       Date:  2018-11-19

2.  Provox 2® and Provox Vega® device life-time: a case-crossover study with multivariate analysis of possible influential factors and duration.

Authors:  Miguel Mayo-Yáñez; Irma Cabo-Varela; Loredana Dovalo-Carballo; Christian Calvo-Henríquez; Alejandro Martínez-Morán; Jesús Herranz González-Botas
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-24       Impact factor: 2.503

3.  Are modern voice prostheses better? A lifetime comparison of 749 voice prostheses.

Authors:  P Kress; P Schäfer; F P Schwerdtfeger; S Rösler
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-29       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.